Compare IMMP & CAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | CAL |
|---|---|---|
| Founded | 1987 | 1878 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.9M | 450.1M |
| IPO Year | N/A | N/A |
| Metric | IMMP | CAL |
|---|---|---|
| Price | $2.73 | $12.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 185.7K | ★ 575.7K |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | $3,306,742.00 | ★ $2,702,018,000.00 |
| Revenue This Year | $292.48 | $5.63 |
| Revenue Next Year | N/A | $2.16 |
| P/E Ratio | ★ N/A | $21.00 |
| Revenue Growth | ★ 31.28 | N/A |
| 52 Week Low | $1.32 | $9.54 |
| 52 Week High | $3.53 | $18.38 |
| Indicator | IMMP | CAL |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 45.44 |
| Support Level | $2.56 | $12.42 |
| Resistance Level | $3.23 | $13.70 |
| Average True Range (ATR) | 0.14 | 0.67 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 23.88 | 22.46 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.